Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Contemporary Pediatrics ; (12): 854-859, 2013.
Article in Chinese | WPRIM | ID: wpr-345692

ABSTRACT

<p><b>OBJECTIVE</b>To investigate impact factors for the efficacy of specific immunotherapy (SIT) in children with dust mite allergic asthma.</p><p><b>METHODS</b>Ninety-nine children with house dust mite allergic asthma received standardized SIT, and the level of asthma control was evaluated after 6 months (S1 stage), 12 months (S2 stage), 18 months (S3 stage), and 24 months (S4 stage) of treatment. The age of first visit, course of asthma, level of asthma severity, initial serum specific immunoglobulin E (sIgE) level, combination with allergic rhinitis or atopic dermatitis, use of inhaled corticosteroids, and local or systemic side effects during treatment were recorded, and their impacts on the level of asthma control were analyzed.</p><p><b>RESULTS</b>As the SIT proceeded, the number of clinically controlled cases increased significantly (P<0.01). The level of asthma control was significantly affected by the age of patients at first visit in S1 and S3 stages, and combination with allergic rhinitis or atopic dermatitis in S1 stage (P<0.05). In all stages of SIT, the controlled cases had significantly higher initial serum sIgE levels than the uncontrolled cases (P<0.05). In S1 and S2 stages, there was a significantly higher proportion of controlled cases among children with a high level of asthma severity than among those with a low level of asthma severity (P<0.05).</p><p><b>CONCLUSIONS</b>There is a positive correlation between long-term efficacy of SIT and the course or the total dose of treatment. Patients with higher initial serum sIgE levels achieve clinical control earlier than those with lower initial serum sIgE levels during SIT.</p>


Subject(s)
Adolescent , Animals , Child , Child, Preschool , Female , Humans , Male , Asthma , Allergy and Immunology , Therapeutics , Desensitization, Immunologic , Immunoglobulin E , Blood , Pyroglyphidae , Allergy and Immunology
2.
Chinese Journal of Contemporary Pediatrics ; (12): 927-930, 2009.
Article in Chinese | WPRIM | ID: wpr-270436

ABSTRACT

<p><b>OBJECTIVE</b>To study the effects of prolonged 75% oxygen exposure on the expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) in the neonatal rat lungs and to elucidate the effects of prolonged exposure of high concentration of oxygen on lung vascular development and its relationship with bronchopulmonary dysplasia (BPD).</p><p><b>METHODS</b>Forty eight Sprague-Dawley rat pups were randomly exposed to air (control group) and 75% oxygen (experimental group) 12 hrs after birth. The rats were sacrificed 7, 14 and 21 days after exposure and their lungs were sampled. The lung sections were stained with hematoxylin and eosin for histological evaluation. Expression of VEGF, VEGFR1 and VEGFR2 protein and mRNA was detected by immunohistochemistry and RT-PCR.</p><p><b>RESULTS</b>After being exposed to 75% oxygen for 21 days, lung tissues had pathological changes as 'new' BPD. Expressions of VEGF protein (10.9 + or - 2.7 vs 30.8 + or - 6.4), VEGFR1 protein (5.4 + or - 1.4 vs 15.6 + or - 3.4) and VEGFR2 protein (11.3 + or - 2.6 vs 21.7 + or - 4.5) on day 21 in the experimental group decreased significantly as compared with the control group (p<0.05). The expression of VEGF mRNA (1.6 vs 3.3), VEGFR1 mRNA (0.4 vs 6.6) and VEGFR2 mRNA (0.5 vs 4.9) on day 21 in the experimental group also decreased significantly as compared with the control group (p<0.05).</p><p><b>CONCLUSIONS</b>Prolonged exposure of high concentration of oxygen may cause BPD possibly by inhibiting lung vascular development in neonatal rats.</p>


Subject(s)
Animals , Female , Humans , Infant, Newborn , Male , Rats , Animals, Newborn , Bronchopulmonary Dysplasia , Lung , Oxygen , Toxicity , RNA, Messenger , Rats, Sprague-Dawley , Vascular Endothelial Growth Factor A , Genetics , Vascular Endothelial Growth Factor Receptor-1 , Genetics , Vascular Endothelial Growth Factor Receptor-2 , Genetics
SELECTION OF CITATIONS
SEARCH DETAIL